NEPT - Neptune Technologies & Bioressources Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.80
+0.06 (+2.19%)
At close: 4:00PM EDT

2.66 -0.14 (-5.00%)
After hours: 4:40PM EDT

Stock chart is not supported by your current browser
Previous Close2.74
Open2.74
Bid2.61 x 2200
Ask2.75 x 2200
Day's Range2.65 - 2.80
52 Week Range0.70 - 4.46
Volume380,541
Avg. Volume920,592
Market Cap223.995M
Beta1.49
PE Ratio (TTM)16.97
EPS (TTM)0.17
Earnings DateJan 10, 2017 - Jan 16, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2008-07-24
1y Target Est3.15
Trade prices are not sourced from all markets
  • CNW Group11 minutes ago

    Neptune Announces First Quarter Results

    Neptune Announces First Quarter Results

  • PR Newswire11 minutes ago

    Neptune Announces First Quarter Results

      Phase I Investment of the Cannabis Business Plan Completed   And Phase II capacity expansion ongoing Q1 Financial and Operational Highlights for the 3-month period ended June 30, 2018 compared to the ...

  • Why Neptune Technologies & Bioressources Inc’s (TSE:NEPT) Investor Composition Impacts Your Returns
    Simply Wall St.6 hours ago

    Why Neptune Technologies & Bioressources Inc’s (TSE:NEPT) Investor Composition Impacts Your Returns

    Today, I will be analyzing Neptune Technologies & Bioressources Inc’s (TSE:NEPT) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure has been found to have anRead More...

  • PR Newswire5 days ago

    Neptune Files Two Patent Applications for Innovative Cannabis Extraction Processes

    LAVAL, QC, Aug. 9, 2018 /PRNewswire/ - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (NEPT.TO) has filed two applications with the United States Patent and Trademark Office (USPTO) for patents related to the extraction of cannabis material. The extraction processes provide highly-efficient methods to obtain cannabinoids and other desired compounds from the cannabis plant at a greater purity than conventional methods. Both processes are applicable to marijuana and hemp and will be incorporated into the company's Good Manufacturing Practices (GMP)-certified extraction facility in Sherbrooke, QC upon approval of the applicable licensing to produce cannabis extract (pursuant to the Access to Cannabis for Medical Purposes Regulations).  As a late-stage applicant, Neptune is currently working with Health Canada authorities to complete the licensing process.

  • CNW Group5 days ago

    Neptune Files Two Patent Applications for Innovative Cannabis Extraction Processes

    LAVAL, QC , Aug. 9, 2018 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (NEPT.TO) has filed two applications with the United States Patent and Trademark Office (USPTO) for patents related to the extraction of cannabis material. The extraction processes provide highly-efficient methods to obtain cannabinoids and other desired compounds from the cannabis plant at a greater purity than conventional methods. Both processes are applicable to marijuana and hemp and will be incorporated into the company's Good Manufacturing Practices (GMP)-certified extraction facility in Sherbrooke, QC upon approval of the applicable licensing to produce cannabis extract (pursuant to the Access to Cannabis for Medical Purposes Regulations).  As a late-stage applicant, Neptune is currently working with Health Canada authorities to complete the licensing process.

  • CNW Group7 days ago

    Perceptive Advisors, LLC inceases its position in Neptune Technologies & Bioressources Inc.

    NEW YORK , Aug. 7, 2018 /CNW Telbec/ - Perceptive Advisors, LLC ("Perceptive Advisors") announces that on December 14, 2017 it acquired, on behalf of certain fund accounts it manages, 200,000 common shares (the "Initial Shares") of Neptune Technologies & Bioressources Inc. ("Neptune") (NEPT.TO) (NEPT), representing approximately 0.25% of the issued and outstanding common shares of Neptune. Immediately prior to the acquisition, Perceptive Advisors owned 7,850,315 common shares representing approximately 9.91% of the issued and outstanding common shares of Neptune. This acquisition increased Perceptive Advisors' position in the common shares of Neptune to 8,050,315, or approximately 10.16% of the issued and outstanding common shares.

  • PR Newswire14 days ago

    Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2018

    LAVAL, QC , July 31, 2018 /PRNewswire/ - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ: NEPT) (TSX: NEPT), announces that it will be holding a conference ...

  • CNW Group14 days ago

    Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2018

    Neptune to Hold Conference Call to Discuss First Quarter Results for the Three Months Period Ended June 30, 2018

  • Investopedia14 days ago

    Penny Stocks to Watch for August 2018

    Penny stock pickers booked modest returns in these tough conditions, while trend followers and dart throwers took losses. The July penny stock list generated mixed returns, with precious metals and biotech headwinds limiting gains while a mid-month crude oil reversal undermined small energy plays.

  • ACCESSWIRE20 days ago

    Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 25, 2018 / If you want a free Stock Review on NEPT sign up now at www.wallstequities.com/registration. Under evaluation this morning are the following equities: Magenta Therapeutics Inc. (MGTA), Matinas BioPharma Holdings Inc. (NYSE AMER: MTNB), MyoKardia Inc. (NASDAQ: MYOK), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • How to make, and avoid losing, money with marijuana stocks
    MarketWatch21 days ago

    How to make, and avoid losing, money with marijuana stocks

    This is an instructive tale of how some investors with the right knowledge just made good money in three marijuana stocks, while others with less knowledge lost money in two marijuana stocks and missed the opportunity to buy the third. To make money in marijuana stocks, investors need to understand the true nature of the companies and the stocks, and have available to them expert guidance. Please click here for an annotated chart of marijuana stock Canopy Growth (CGC) For the sake of full transparency, this is exactly the same chart that was published previously.

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch25 days ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • Harry Boxer’s four health-care stocks to watch
    MarketWatchlast month

    Harry Boxer’s four health-care stocks to watch

    In focus: Arbutus Biopharma, Marinus Pharmaceuticals, Neptune Technologies & Bioressources and OPKO Health.

  • MarketWatch2 months ago

    Investors are making stoner moves by buying marijuana stocks at the wrong time

    The average investor is pouring money into the stocks while professionals are dumping themParamount PicturesDon’t let marijuana stocks go up in smoke. Mom-and-pop investors have become excited about the use of marijuana and cannabis. Unfortunately, those investors have not had the proper guidance or expertise about when and how to buy marijuana stocks.

  • InvestorPlace2 months ago

    Marijuana Stocks: Two to Consider, Two to Avoid

    The marijuana legalization movement is picking up speed. Uruguay became the first nation in the Americas to permit recreational marijuana usage in 2014. Marijuana stocks were waiting for a bigger market to come online.

  • What Are Neptune’s Key Growth Strategies for Fiscal 2019?
    Market Realist2 months ago

    What Are Neptune’s Key Growth Strategies for Fiscal 2019?

    Neptune Technologies and Bioressources (NEPT) is based in Quebec, Canada. The company develops various turnkey solutions and offers specialty ingredients that include the MaxSimil and Biodroga nutrition business. The below diagram shows the highlights of Neptune’s performance in fiscal 2018.

  • Neptune Stock Rises on Multiyear Contract with Canopy Growth
    Market Realist2 months ago

    Neptune Stock Rises on Multiyear Contract with Canopy Growth

    Over the last one week, Neptune Technologies and Bioressources (NEPT) has risen ~94%. The rise in the company’s stock was triggered by the news of the company entering a multiyear agreement with Canopy Growth (CGC) to supplement its extraction, refinement, and extract product formulation capacity. The agreement could advance Neptune’s aim to expand its footprint in the cannabis industry.

  • Analysts See Upside of 35% for Neptune for Next 12 Months
    Market Realist2 months ago

    Analysts See Upside of 35% for Neptune for Next 12 Months

    Neptune Technologies and Bioressources (NEPT) is a wellness product company based in Quebec, Canada. With the legalization of cannabis in Canada, the company has been making big plans to expand in the cannabis market and leverage its scientific and technological expertise to expand across this potential growth market. Some of the largest players in this segment include Aurora Cannabis (ACB), Canopy Growth (CGC), and MedReleaf (MEDFF), which saw their stock prices rise during the first week of June when the Cannabis Act was approved in Canada. ...

  • Here's Why Neptune Technologies & Bioressources Rose as Much as 23.8% Today
    Motley Fool2 months ago

    Here's Why Neptune Technologies & Bioressources Rose as Much as 23.8% Today

    The marijuana stock is now up 353% in the last year.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: Neptune Technologies & Bioressources and NeuroMetrix

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a multi-year extraction agreement with Canopy Growth that sent shares of Neptune Technologies flying higher on Tuesday. Shares of NeuroMetrix also scored ...

  • CNW Group2 months ago

    Neptune Announces Multi-year Agreement with Canopy Growth to Provide Extracted Cannabis Products

    LAVAL, QC , June 19, 2018 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NEPT) (NEPT.TO), today announced that it entered into a multi-year agreement with Canopy Growth (WEED.TO) (CGC). Under the terms of the agreement, Neptune will supplement Canopy Growth's extraction, refinement, and extract product formulation capacity. "We are truly excited to partner with such a great company as Canopy Growth.

  • PR Newswire2 months ago

    Neptune Announces Multi-year Agreement with Canopy Growth to Provide Extracted Cannabis Products

    LAVAL, QC, June 19, 2018 /PRNewswire/ - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NEPT) (NEPT.TO), today announced that it entered into a multi-year agreement with Canopy Growth (WEED.TO) (CGC). Under the terms of the agreement, Neptune will supplement Canopy Growth's extraction, refinement, and extract product formulation capacity. "We are truly excited to partner with such a great company as Canopy Growth.

  • ACCESSWIRE2 months ago

    Free Technical Reports on MannKind and Three Additional Biotech Equities

    This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).

  • ACCESSWIRE2 months ago

    Wired News - Idera Pharma Announced Phase-2 Trial Results of IMO-8400 in Adult Patients with Dermatomyositis

    LONDON, UK / ACCESSWIRE / June 14, 2018 / If you want access to our free research report on Idera Pharma, Inc. (NASDAQ: IDRA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IDRA as the Company's latest news hit the wire. On June 12, 2018, the Cambridge-based Company announced that the Phase-2 clinical trial assessing IMO-8400 in adult patients with dermatomyositis did not meet its primary endpoint.

  • CNW Group2 months ago

    Neptune Announces Fourth Quarter and Year-end Results

    Neptune Announces Fourth Quarter and Year-end Results